U.S. Clinical Oncology Next Generation Sequencing Market Size, Revenue, Growth, Trend & Forecast Analysis, 2020 - 2027, By Workflow, By Technology, By End-Use, By Country, & By Region
U.S. Clinical Oncology Next Generation Sequencing Market Report Overview
U.S. clinical oncology next generation sequencing market is anticipated to reach USD 3.2 billion by 2027, growing at a compound annual growth (CAGR) of 18.4% over the forecast period (2020-2027). The market has been observed to be growing at a steady growth rate over the last three years, however with the impact of COVID-19 pandemic globally, the business conditions are expected to change. The market size may reduce significantly or increase with a spike depending on how the value chain has been affected in the entire process.
Players that are operational in the market for a longer period of time are anticipated to absorb the sudden changes, losses and increased operational costs better than those who have recently entered the market. The report focuses on numerous factors that are anticipated to impact the market growth directly and indirectly. The report categorically analyses the growth patterns of different segments based on multiple derivation models.
Both the qualitative and quantitative aspects have been covered under the report. The U.S. Clinical Oncology Next Generation Sequencing market report includes market size, drivers, restraints, opportunities and trends that will help you understand the market dynamics in detail. Moreover, the report will include market estimates & forecasts in terms of revenue for the overall market along with the segments mentioned in the study. The report focuses on providing a holistic view of the entire market scenario from multiple unmatched detailed analysis mentioned in the report.
What to expect from the report?
S. Clinical Oncology Next Generation Sequencing Total Available Market (TAM) Size
S. Clinical Oncology Next Generation Sequencing Serviceable Available Market (SAM) Size
Business Implications of COVID-19 on the Overall Market
Market Share/ Revenue Share (%) of Top Market Players in Total Market Size (2019)
Market Size & Forecast (2016-2027) At Country & Regional Level, By Segments
Overview & Analysis of Key Players Operating in the Market
Key Highlights:
Parameters
Description
COVID-19
Impact of COVID-19 on overall business scenario
U.S. Clinical Oncology Next Generation Sequencing Market Revenue 2020
Global market revenue in 2020 will be derived taking into various micro & macro level factors; along with COVID-19 pandemic
Competitive Analysis
Company Market Share Analysis, 2019 (%)
Supply Chain Analysis
Analysis pertaining to several participants of supply chain such as raw material suppliers, distributors, & OEMs along with others will be highlighted in the study
Data Source
Primary & Secondary Research, Internal Data Base & Company Annual Reports
Table of Contents Chapter 1. Research Methodology & Data Sources 1.1. Data Analysis Models 1.2. Research Scope & Assumptions 1.3. List of Primary & Secondary Data Sources Chapter 2. Executive Summary Chapter 3. U.S. Clinical Oncology Next Generation Sequencing Market: Industry Analysis 3.1. Market segmentation 3.2. Supply chain analysis 3.3. Porter’s 5 forces analysis 3.4. PEST analysis 3.5. Market Dynamics 3.5.1. Market driver analysis 3.5.2. Market restraint analysis 3.5.3. Market opportunity analysis 3.6. Company Market Share Analysis, 2019 Chapter 4. U.S. Clinical Oncology Next Generation Sequencing Market: Workflow Insights 4.1. Global Workflow Historic Market Data & Future Forecasts, 2016-2027 4.2. NGS Sequencing 4.2.1. Historic Market Data & Future Forecasts, 2016-2027 4.2.2. Historic Market Data & Future Forecasts by Region, 2016-2027 4.3. NGS Pre-Sequencing 4.3.1. Historic Market Data & Future Forecasts, 2016-2027 4.3.2. Historic Market Data & Future Forecasts by Region, 2016-2027 4.4. NGS Data Analysis 4.4.1. Historic Market Data & Future Forecasts, 2016-2027 4.4.2. Historic Market Data & Future Forecasts by Region, 2016-2027 4.5. Others 4.5.1. Historic Market Data & Future Forecasts, 2016-2027 4.5.2. Historic Market Data & Future Forecasts by Region, 2016-2027 Chapter 5. U.S. Clinical Oncology Next Generation Sequencing Market: Technology Insights 5.1. Global Technology Historic Market Data & Future Forecasts, 2016-2027 5.2. Whole Genome Sequencing 5.2.1. Historic Market Data & Future Forecasts, 2016-2027 5.2.2. Historic Market Data & Future Forecasts by Region, 2016-2027 5.3. Whole ERoche Sequencing (454 Life Sciences)n Sequencing 5.3.1. Historic Market Data & Future Forecasts, 2016-2027 5.3.2. Historic Market Data & Future Forecasts, By Region, 2016-2027 5.4. Targeted Sequencing & Resequencing 5.4.1. Historic Market Data & Future Forecasts, 2016-2027 5.4.2. Historic Market Data & Future Forecasts by Region, 2016-2027 5.5. Others 5.5.1. Historic Market Data & Future Forecasts, 2016-2027 5.5.2. Historic Market Data & Future Forecasts by Region, 2016-2027 Chapter 6. U.S. Clinical Oncology Next Generation Sequencing Market: End-Use Insights 6.1. Global End-Use Historic Market Data & Future Forecasts, 2016-2027 6.2. Clinical Research 6.2.1. Historic Market Data & Future Forecasts, 2016-2027 6.2.2. Historic Market Data & Future Forecasts by Region, 2016-2027 6.3. Hospitals & Clinics 6.3.1. Historic Market Data & Future Forecasts, 2016-2027 6.3.2. Historic Market Data & Future Forecasts, By Region, 2016-2027 6.4. Pharma & Biotech Entities 6.4.1. Historic Market Data & Future Forecasts, 2016-2027 6.4.2. Historic Market Data & Future Forecasts by Region, 2016-2027 6.5. Others 6.5.1. Historic Market Data & Future Forecasts, 2016-2027 6.5.2. Historic Market Data & Future Forecasts by Region, 2016-2027 Chapter 7. Company Profiles 7.1. Caris Life Sciences 7.1.1. Company Description 7.1.2. Financial Highlights 7.1.3. Product Portfolio 7.1.4. Strategic Initiatives 7.2. Paradigm Diagnostics, Inc 7.2.1. Company Description 7.2.2. Financial Highlights 7.2.3. Product Portfolio 7.2.4. Strategic Initiatives 7.3. Foundation Medicine Inc. 7.3.1. Company Description 7.3.2. Financial Highlights 7.3.3. Product Portfolio 7.3.4. Strategic Initiatives 7.4. GnuBIO (Bio-Rad) 7.4.1. Company Description 7.4.2. Financial Highlights 7.4.3. Product Portfolio 7.4.4. Strategic Initiatives 7.5. Knome Inc. 7.5.1. Company Description 7.5.2. Financial Highlights 7.5.3. Product Portfolio 7.5.4. Strategic Initiatives 7.6. BGI (Complete Genomics) 7.6.1. Company Description 7.6.2. Financial Highlights 7.6.3. Product Portfolio 7.6.4. Strategic Initiatives 7.7. Qiagen NV 7.7.1. Company Description 7.7.2. Financial Highlights 7.7.3. Product Portfolio 7.7.4. Strategic Initiatives 7.8. Agilent Technologies 7.8.1. Company Description 7.8.2. Financial Highlights 7.8.3. Product Portfolio 7.8.4. Strategic Initiatives 7.9. Roche Sequencing (454 Life Sciences) 7.9.1. Company Description 7.9.2. Financial Highlights 7.9.3. Product Portfolio 7.9.4. Strategic Initiatives 7.10. Illumina Incorporated 7.10.1. Company Description 7.10.2. Financial Highlights 7.10.3. Product Portfolio 7.10.4. Strategic Initiatives List of Tables Table 1 U.S. Clinical Oncology Next Generation Sequencing Market Market Data & Future Forecasts, 2016-2027 (USD Billion) Table 2 U.S. Clinical Oncology Next Generation Sequencing Market Data & Future Forecasts, By Region, 2016-2027 (USD Billion) Table 3 U.S. Clinical Oncology Next Generation Sequencing Market Data & Future Forecasts, By Workflow, 2016-2027 (USD Billion) Table 4 U.S. Clinical Oncology Next Generation Sequencing Market Data & Future Forecasts, By Technology, 2016-2027 (USD Billion) Table 5 U.S. Clinical Oncology Next Generation Sequencing Market Data & Future Forecasts, By End-Use, 2016-2027 (USD Billion) Table 6 NGS Sequencing Market Data & Future Forecasts, 2016-2027 (USD Billion) Table 7 NGS Pre-Sequencing Market Data & Future Forecasts, 2016-2027 (USD Billion) Table 8 NGS Data Analysis Market Data & Future Forecasts, 2016-2027 (USD Billion) Table 9 Others Market Data & Future Forecasts, 2016-2027 (USD Billion) Table 11 Whole Genome Sequencing Market Data & Future Forecasts, 2016-2027 (USD Billion) Table 12 Whole ERoche Sequencing (454 Life Sciences)n Sequencing Market Data & Future Forecasts, 2016-2027 (USD Billion) Table 13 Targeted Sequencing & Resequencing Market Data & Future Forecasts, 2016-2027 (USD Billion) Table 14 Others Market Data & Future Forecasts, 2016-2027 (USD Billion) Table 15 Clinical Research Market Data & Future Forecasts, 2016-2027 (USD Billion) Table 16 Hospitals & Clinics Market Data & Future Forecasts, 2016-2027 (USD Billion) Table 17 Pharma & Biotech Entities Market Data & Future Forecasts, 2016-2027 (USD Billion) Table 18 Others Market Data & Future Forecasts, 2016-2027 (USD Billion) List of Figures Fig.1 Data Analysis Model Fig.2 U.S. Clinical Oncology Next Generation Sequencing Market, by 2016-2027 (USD Billion) Fig.3 U.S. Clinical Oncology Next Generation Sequencing Market Segmentation Fig.4 Supply chain analysis Fig.5 U.S. Clinical Oncology Next Generation Sequencing Market Driver Anlaysis Fig.6 U.S. Clinical Oncology Next Generation Sequencing Market Restraint Analysis Fig.7 U.S. Clinical Oncology Next Generation Sequencing Market Opportunity Analysis Fig.8 Porters 5 Forces Model Fig.9 PEST Analysis- U.S. Clinical Oncology Next Generation Sequencing Market Fig.10 Company Market Share Analysis, 2019
U.S. Clinical Oncology Next Generation Sequencing Market Segmentation:
U.S. Clinical Oncology Next Generation Sequencing Market, By Workflow (2016-2027)
NGS Sequencing
NGS Pre-Sequencing
NGS Data Analysis
Others
U.S. Clinical Oncology Next Generation Sequencing Market, By Technology (2016-2027)
Whole Genome Sequencing
Whole ERoche Sequencing (454 Life Sciences)n Sequencing
Targeted Sequencing & Resequencing
Others
U.S. Clinical Oncology Next Generation Sequencing Market, By End-Use (2016-2027)
Clinical Research
Hospitals & Clinics
Pharma & Biotech Entities
Others
Major Players Operating in the U.S. Clinical Oncology Next Generation Sequencing Market:
Caris Life Sciences
Paradigm Diagnostics, Inc
Foundation Medicine Inc.
GnuBIO (Bio-Rad)
Knome Inc.
BGI (Complete Genomics)
Qiagen NV
Agilent Technologies
Roche Sequencing (454 Life Sciences)
Illumina Incorporated
Choose License Type
Each market study on Reports Globe will be revised based on COVID-19 impact analysis
How can we help you?
Our salient features
Best Solution
We will help you understand value propositions of various reports across numerous domains and suggest the best possible solution to suffice your research needs.
Customized Research
Our team of analysts and consultants provide assistance for customized research requirements
Max ROI
Guaranteed maximum assistance to help you get your reports at the optimum prices, thereby ensuring maximum returns on investment.
24/7 Support
24X7 availability to help you through the buying process as well as answer any of your doubts.
